Abstract
Chemical ablation using the transcoronary arterial system has a lengthy but arduous history. Although it has shown to be efficacious in controlling ventricular arrhythmias, safety concerns from cannulation of the coronary arterial system to unwanted ethanol downstream effects have limited transcoronary ethanol ablation (TCEA)'s use. Retrograde coronary venous ethanol ablation (RCVEA) has shown promising results. Although it appears to be in its infancy, RCVEA appears to be the future of chemical ablation in comparison to TCEA due to its increased safety and efficacy. Prospective randomized trial data is needed for this adjunctive treatment to radiofrequency ablation.
Original language | English (US) |
---|---|
Pages (from-to) | 63-74 |
Number of pages | 12 |
Journal | Cardiac Electrophysiology Clinics |
Volume | 15 |
Issue number | 1 |
DOIs | |
State | Published - Mar 2023 |
Keywords
- Ablation
- Alcohol
- Annular vein
- Heart Ventricles
- Tachycardia, Ventricular
- Prospective Studies
- Ethanol
- Humans
- Arrhythmias, Cardiac/surgery
- Catheter Ablation
- Treatment Outcome
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Physiology (medical)